A set of general principles can guide preclinical testing strategies for evaluating the tumorigenicity of regenerative medicine products.
No takes yet. Share an insight, caveat, or question.
Alexander M. Bailey (2012) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: